Teresa Fogaren
Nurse Practitioner · Boston, MANPI 1093260093
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,671 of the $101,533 with a category attached, or 85.4%. Johnson & Johnson accounts for 94.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $49,322 and has fallen 70.0% since, to $14,820 in 2025. Among nurse practitioner clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $763.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$96K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Adaptive Biotechnologies Corporation$800
- Incyte Corporation$130
- Legend Biotech USA Inc.$118
- Epizyme, Inc.$74
- plus $450 from 15 others
What the payments were for
- Consulting fees$8001%
- Speaking & faculty fees$86,67185%
- Travel & lodging$10,23810%
- Food & beverage$3,5273%
- Education$2970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 99 | $95,635 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $4,325 |
| Adaptive Biotechnologies Corporation | 1 | $800 |
| Incyte Corporation | 1 | $130 |
| Legend Biotech USA Inc. | 7 | $118 |
| Epizyme, Inc. | 1 | $74 |
| Bristol Myers Squibb | 3 | $69 |
| Amgen | 4 | $67 |
| Seagen Inc. | 2 | $61 |
| Genentech USA, Inc. | 1 | $32 |
| GSK | 1 | $26 |
| Pfizer | 1 | $26 |
| Syndax Pharmaceuticals, Inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $23 |
| Novartis | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Sanofi | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$101,533 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 98 | $1,472,803 |
| RevlimidLenalidomide | 88 | $1,436,657 |
| NinlaroIxazomib Citrate | 62 | $783,754 |
| VyndamaxTafamidis | 32 | $725,580 |
| PomalystPomalidomide | 35 | $693,666 |
| Lenalidomide | 11 | $156,579 |
| OxycontinOxycodone Hcl | 39 | $33,269 |
| EliquisApixaban | 26 | $29,028 |
| Acyclovir | 141 | $2,534 |
| Fentanyl | 19 | $1,149 |
| Gabapentin | 44 | $775 |
| Dexamethasone | 65 | $623 |
| Torsemide | 24 | $575 |
| Omeprazole | 27 | $444 |
| Oxycodone Hcl | 32 | $347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $69 | $1,436,65788 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $4,325 | $783,75462 claims |
| PfizerVyndamax, Eliquis | $26 | $754,60858 claims |
| Lilly USA, LLCOlanzapine | $18 | $22619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Other nurse practitioner in Boston
- Carolyn MetivierBoston$93K
- Miu Lai NgBoston$33K
- Lauren BurkeBoston$26K
- Ashley HilmesBoston$24K
- Kristina SkarbinskiBoston$24K
- Hilary UgrasBoston$19K
- Colleen TigheBoston$17K
- Stephanie McDonaldBoston$17K
- Alichia PatonBoston$12K
- Reava KhristenkoBoston$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.